Immupharma (LON:IMM)‘s stock had its “buy” rating reiterated by analysts at Berenberg Bank in a research note issued on Monday, April 16th.
Several other research analysts have also commented on the stock. Northland Securities reiterated a “buy” rating on shares of Immupharma in a research note on Tuesday, April 17th. Northland Capital Partners reiterated a “buy” rating and set a GBX 181 ($2.59) price objective on shares of Immupharma in a research note on Friday, March 23rd. Finally, FinnCap reiterated a “buy” rating and set a GBX 237 ($3.39) price objective on shares of Immupharma in a research note on Thursday, December 21st.
LON IMM opened at GBX 44 ($0.63) on Monday. Immupharma has a 52 week low of GBX 44 ($0.63) and a 52 week high of GBX 193.74 ($2.77).
ILLEGAL ACTIVITY NOTICE: “Immupharma (IMM) Receives “Buy” Rating from Berenberg Bank” was published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://macondaily.com/2018/04/17/berenberg-bank-reaffirms-buy-rating-for-immupharma-imm.html.
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease.
Receive News & Ratings for Immupharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immupharma and related companies with MarketBeat.com's FREE daily email newsletter.